Company · founded 2008
Astraea Therapeutics (United States)
Mountain View, United States · astraeatherapeutics.com
- Citations, last 5 years
- 48
- Works, last 5 years
- 18
- h-index
- 40
- Scientists listed
- 4
- Grants since 2016
- 13
Grants received
2021–2024 · cooperative agreement · U01
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
Kenneth Alan Perkins · Astraea Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · cooperative agreement · U01
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
Kenneth Alan Perkins · Astraea Therapeutics (United States) · funded by National Institutes of Health
2021–2024 · cooperative agreement · U01
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
Kenneth Alan Perkins · Astraea Therapeutics (United States) · funded by National Institutes of Health
2021–2024 · cooperative agreement · U01
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
Kenneth Alan Perkins · Astraea Therapeutics (United States) · funded by National Institutes of Health
2020–2022 · cooperative agreement · U18
VALIDATING THE NOCICEPTIN RECEPTOR FOR TREATING CRAVING AND WITHDRAWAL-ASSOCIATED AFFECT IN COCAINE ADDICTION PHARMACOTHERAPY
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · cooperative agreement · UH3
Development of Next-generation Pharmacotherapy for Opioid Use Disorders
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · cooperative agreement · UH3
Development of Next-generation Pharmacotherapy for Opioid Use Disorders
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · cooperative agreement · UG3
Development of Next-generation Pharmacotherapy for Opioid Use Disorders
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2019–2022 · cooperative agreement · UG3
Development of Next-generation Pharmacotherapy for Opioid Use Disorders
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · cooperative agreement · UH3
Development of Next-generation Pharmacotherapy for Opioid Use Disorders
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2018–2021 · cooperative agreement · U01
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2018–2021 · cooperative agreement · U01
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health
2018–2022 · cooperative agreement · U01
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE
Nurulain T Zaveri · Astraea Therapeutics (United States) · funded by National Institutes of Health